{
  "report_rows": [
    {
      "kpi": "Adjusted diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$2.78 vs. cons $2.75",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$987M vs. cons $979.9M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "DSA revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$596M vs. cons $592.1M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Non-GAAP EPS (FY26)",
      "prediction": "UNCHANGED",
      "answer": "guide $10.80-$11.30 vs. cons $11.08",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic revenue (FY26)",
      "prediction": "UNCHANGED",
      "answer": "guide (1.5)%-(0.5)% vs. prior company range (1.5)%-(0.5)%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "DSA book-to-bill (Q2/H2 commentary)",
      "prediction": "BETTER",
      "answer": "guide ~1.02x vs. cons 0.99x",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -2.0,
  "day1_confidence": "LOW",
  "day5_residual_pct": -5.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 maintained FY outlook drives modest H2 revision risk",
  "day5_confidence": "LOW"
}